| 000 | 01294 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250514063641.0 | ||
| 264 | 0 | _c20030610 | |
| 008 | 200306s 0 0 eng d | ||
| 022 | _a1568-0118 | ||
| 024 | 7 |
_a10.2174/1568011033353533 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTenzer, A | |
| 245 | 0 | 0 |
_aPotentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. _h[electronic resource] |
| 260 |
_bCurrent medicinal chemistry. Anti-cancer agents _cJan 2003 |
||
| 300 |
_a35-46 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAlkaloids |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemistry |
| 650 | 0 | 4 |
_aCaffeine _xchemistry |
| 650 | 0 | 4 |
_aCell Cycle Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aDNA Damage _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aG2 Phase _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aStaurosporine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aXanthines _xchemistry |
| 700 | 1 | _aPruschy, M | |
| 773 | 0 |
_tCurrent medicinal chemistry. Anti-cancer agents _gvol. 3 _gno. 1 _gp. 35-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1568011033353533 _zAvailable from publisher's website |
| 999 |
_c12471564 _d12471564 |
||